In pooled clinical trials that led to accelerated FDA approval, 1 year of Ferriprox® treatment offered a decrease in serum ferritin level in patients whose prior chelation therapy was inadequate.
Decrease in cardiac iron load
In pooled clinical trials that led to accelerated FDA approval, 1 year of Ferriprox treatment offered a decrease in cardiac iron load in patients whose prior chelation therapy was inadequate.
Reduction in liver iron concentration (LIC)
In pooled clinical trials that led to accelerated FDA approval, 1 year of Ferriprox treatment offered a decrease in LIC in patients whose prior chelation therapy was inadequate.
You are now leaving ferriprox.com
Please be aware that the sponsors of this site are not responsible for content on the site you are about to enter.